The role of liposomes in drug delivery and diagnostic imaging: A review

Veterinary Radiology and Ultrasound

Volumn 41, Issue 2, 2000, Pages 100-107

  Matteucci, Mark L ^a   Thrall, Donald E ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DRUG CARRIER; LIPOSOME; VETERINARY DRUG;

ANIMAL; ANIMAL DISEASE; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; METHODOLOGY; RADIOGRAPHY; REVIEW;

ANIMAL DISEASES; ANIMALS; CONTRAST MEDIA; DIAGNOSTIC IMAGING; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; LIPOSOMES; VETERINARY DRUGS;

EID: 0034153664     PISSN: 10588183     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1740-8261.2000.tb01462.x     Document Type: Review

References (55)

1. Lasic DD. Novel applications of liposomes. Trends in Biotechnology 1998;16:307-321.
2. Torchilin VP. Liposomes as delivery agents for medical imaging. Molecular Medicine Today 1996;6:242-249.
3. Gregoriadis G, Florence AT. Liposomes in drug delivery-clinical, diagnostic, and ophthalmic potential. Drugs 1993;45:15-28.
4. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends in Pharmacological Science 1994;15:215-220.
5. Allen TM. Liposomes - opportunities in drug delivery. Drugs 1997;54(suppl. 4):8-14.
6. Lasic DD, Papahadjopoulos D. Liposomes Revisited. Science 1995; 267:1275-1276.
7. Torchilin VP. Polymer-coated long-circulating microparticulate pharmaceuticals. Journal of microencapsulation. 1998;15:1-19.
8. Lasic D, Martin F. Stealth Liposomes. Boca Raton, CRC Press 1995.
9. Kruth SA. Biological response modifiers: interferons, interleukins, recombinant products, liposomal products. Vet Clin North Am Small Anim Pract 1998;28:269-295.
10. Vail DM, Kravis LD, Cooley AJ, Chun R, MacEwen EG. Preclinical trial of Doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemotherapy and Pharmacology 1997;39:410-416.
11. Thamm DH, Vail DM. Preclinical evaluation of a sterically stabilized liposome-encapsulated cisplatin in clinically normal cats. AJVR 1998;59:286-290.
12. MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. Journal of National Cancer Institute 1989;81:935-938.
13. Kisseberth WC, MacEwen EG, Helfand SC, Vail DM, London CL, Keller E. Response to liposome-encapsulated doxorubicin (TLC D-99) in a dog with myeloma. JVIM 1995;9:425-428.
14. Vail DM, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clinical Cancer Research 1995;1:1165-1170.
15. Fox LE, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma - a multicenter randomized double blind study. Cancer Biotherapy 1995;10:125-130.
16. Krawiec DR, McKiernan BC, Twardock AR, et al. Use of an amphotericin b lipid complex for treatment of blastomycosis in dogs. JAVMA 1996;209:2073-2075.
17. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology 1965;13:238-252.
18. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996;380:561-562.
19. Phillips WT, Rudolph AS, Coins B, Timmons JH, Klipper R, Blumhardt R. A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Nuclear Medicine Biology 1992;5:539-547.
20. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proceedings of the national academy of science. USA. 1991;88:11460.
21. Wu NZ, Da D, Rudoll TL, Needhara D, Whorton AR, Dewhirst MW. Increased micro vascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Research 1993; 53:3765-3770.
22. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvascular Research 1986;31:288-305.
23. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing c-26 colon carcinoma. Cancer Research 1992; 52:6774-6781.
24. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene glycol coated liposomes. Cancer Research 1994; 54:987-992.
25. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Research 1994;54:3352-3356.
26. Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ, Bankert RB. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Research 1993;53:3964-3967.
27. Vaage J, Mayhew E, Lasic DD, Martin FJ. Therapy of primary and metastatic mouse mammary tumors with doxorubicin encapsulated in long circulating liposomes. International Journal of Cancer. 1992;51:942.
28. Kurzman ID, MacEwen EG, Rosenthal RC, et al Adjuvant therapy for osteosarcoma in dogs: Results of randomized clinical trials using combined liposome encapsulated muramyl tripeptide and cisplatin. Clinical Cancer Research 1995;1:1595.
29. th Annual Conference, Pacific Grove, 1996;74.
30. Allen TM. Antibody-mediated targeting of long-circulating (Stealth) liposomes. Journal of Liposome Research 1994;4:1-7.
31. Ahmad I, Allen TM. Antibody-mediated specific binding and cytotoxicity of liposomes-entrapped doxorubicin to lung cancer cells in vitro. Cancer Research 1992;52:4817.
32. Ahmad I, Longnecker M, Samuel J, Allen TM. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can erradicate lung cancer in mice. Cancer Research 1993;53:1484
33. Dewhirst MW. Future directions in hyperthermia biology. International Journal of Hyperthermia 1994;10:339-345.
34. Merlin JL. In vitro evaluation of the association of thermosensitive liposome-encapsulated doxorubicin with hyperthermia. European Journal of Cancer 1991;27:1031-1034.
35. Kakimuna K, Tanaka R, Takahashi H, Sekihara Y, Watanabe M, Kuroki M. Drug delivery to the brain using thermosensitive liposomes and local hyperthermia. International Journal of Hyperthermia 1996;12:157-165.
36. Huang SK, Stauffer PR, Hong K, et al. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Research 1994;54:2186-2191.
37. Hattori M, Matsui N, Ohta H, et al. Antitumor effect of thermosensitive CDDP-liposomes on human osteosarcoma cells in culture. Nippon-Zasshi 1992;66:476-484.
38. Gaber MH, Wu NZ, Hong K, Huang SK, Dewhirst MW, Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int. J. Radiation Oncology Biol. Phys. 1996;36:1177-1187.
39. Dewhirst MW, Prosnitz L, Thrall DE, et al. Hyperthermic treatment of malignant disease: current status and a view toward the future. Seminars in Oncology 1997;24(6):616-625.
40. Torchilin VP. Handbook of Targeted Delivery Of Imaging Agents Boca Raton, CRC Press, 1995.
41. Seltzer SE. The role of liposomes in diagnostic imagine. Radiology 1989;171:19-21.
42. White C, Slifkin M, Seltzer SE, et al. Biodistribution and clearance of contrast carrying MREV liposomes. Investigative Radiology 1990;25: 1125-1129.
43. Trubetskoy VS, Torchilin VP. Polyethyleneglycol-based micelles as carriers for delivery of therapeutic and diagnostic agents. S.T.P. Pharma Sci. 1996;6:79-86.
44. Caride VJ. Liposomes as carriers of imaging agents. Critical Rev. in Therapeutic Drug Carrier Systems 1985;1:121-153.
45. Gupta H, Weissleder R. Targeted contrast agents in MR imaging. MRI Clinics of North America 1996;4(1):171-184.
46. Unger EC, Shen DK, Fritz TA. Status of liposomes as MR contrast agents. JMRI 1993;3:195-198.
47. Tilcock C, Unger E, Cullis P, MacDougall P. Liposomal Gd-DTTA: preparation and characterization of relaxivity. Radiology 1989;171:77-80.
48. Unger EC, Winokur T, MacDougall P, et al. Hepatic metastasis: liposomal Gd-DTPA-enhanced MR imaging. Radiology 1989;171:81-85.
49. Goins B, Klipper R, Rudolph AS, Phillips WT. Use of technetium-99m-liposomes in tumor imaging. Journal of Nuclear Medicine 1994;35: 1491-1498.
50. Goins B, Klipper R, Rudolph AS, Cliff RO, Blumhardt R, Phillips WT. Biodistribution and imaging studies of technetium-99m-labeled liposomes in rats with focal infection. Journal of Nuclear Medicine 1993;34: 2160-2168.
51. Maresca G, Summaria V, Colagrande C, Manfredi R, Calliada F. New prospects for ultrasound contrast agents. European Journal of Radiology 1998;27:S171-S178.
52. Unger E, Shen D, Fritz T, et al. Gas-filled lipid bilayers as ultrasound contast agents. Investigative Radiology 1994;29(2):S134-S136.
53. Morgan JR, Williams LA, Howard CB. Technetium-labeled liposomes for deep-seated infection. British Journal of Radiology 1985;58:35-39.
54. Grunder W, Biesold M, Wagner M, Werner A. Improved nuclear magnetic resonance microscopic visualization of joint cartilage using liposome entrapped contrast agents. Investigative Radiology 1998;4:193-202.
55. Martinez MN. Use of pharmokinetics in veterinary medicine. Article II - volume, clearance, and half-life. JAVMA 1998;213:1122-1127.